evelo-logo.png
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting
May 13, 2021 07:00 ET | Evelo Biosciences, Inc.
–On-track to initiate clinical development of EDP2939 in 2022– CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company...
evelo-logo.png
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
April 29, 2021 07:00 ET | Evelo Biosciences, Inc.
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief...
evelo-logo.png
Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
April 22, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
April 20, 2021 16:01 ET | Evelo Biosciences, Inc.
–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting– –Meaningful improvements over placebo on clinical scores, including new data released on key...
evelo-logo.png
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
April 15, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
evelo-logo.png
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
April 05, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
evelo-logo.png
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
March 23, 2021 03:00 ET | Evelo Biosciences, Inc.
-- Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in...
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
March 09, 2021 07:00 ET | Evelo Biosciences, Inc.
–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now...
evelo-logo.png
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021
March 02, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
evelo-logo.png
Evelo Biosciences Appoints John A. Hohneker, M.D. to Board of Directors
February 16, 2021 07:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...